Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 49.89 CNY 0.26% Market Closed
Market Cap: 37B CNY

Hangzhou Tigermed Consulting Co Ltd
Deferred Income Tax

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Hangzhou Tigermed Consulting Co Ltd
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Deferred Income Tax
ÂĄ184.3m
CAGR 3-Years
-5%
CAGR 5-Years
15%
CAGR 10-Years
47%
WuXi AppTec Co Ltd
SSE:603259
Deferred Income Tax
ÂĄ434m
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Deferred Income Tax
ÂĄ324.6m
CAGR 3-Years
19%
CAGR 5-Years
38%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Deferred Income Tax
ÂĄ73.2m
CAGR 3-Years
-23%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Genscript Biotech Corp
HKEX:1548
Deferred Income Tax
$5.6m
CAGR 3-Years
-17%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Founded in 2004, Hangzhou Tigermed Consulting Co., Ltd. emerged as a pivotal player in the flourishing landscape of clinical research services within the pharmaceutical and biotechnology sectors. As a leading contract research organization (CRO), Tigermed has meticulously woven a fabric of comprehensive solutions that span from drug development to clinical trial management. Their expertise extends across various therapeutic areas, underpinning a business model that thrives on facilitating the intricate process through which innovative drugs make their way from concept to market. The company’s robust portfolio of services encompasses clinical operations, regulatory submissions, data management, and biostatistics, effectively addressing the myriad needs of drug development companies looking to streamline operations and accelerate time-to-market. Tigermed’s revenue model primarily revolves around contracts and partnerships with pharmaceutical and biotech companies seeking external expertise in clinical trials. The company's proficiency in managing multinational projects, especially within China and the broader Asia-Pacific region, provides an edge in a competitive global market that increasingly values speed and localized knowledge. Rather than merely providing traditional consulting services, Tigermed capitalizes on cutting-edge technology and a deep understanding of regional regulatory frameworks to offer a seamless and efficient trial process. In doing so, it captures the growing demand for outsourcing drug development work, ensuring steady revenue streams while solidifying its status as a vital partner in the relentless pursuit of medical innovation.

Intrinsic Value
53.36 CNY
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Hangzhou Tigermed Consulting Co Ltd's Deferred Income Tax?
Deferred Income Tax
184.3m CNY

Based on the financial report for Sep 30, 2025, Hangzhou Tigermed Consulting Co Ltd's Deferred Income Tax amounts to 184.3m CNY.

What is Hangzhou Tigermed Consulting Co Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
47%

Over the last year, the Deferred Income Tax growth was -10%. The average annual Deferred Income Tax growth rates for Hangzhou Tigermed Consulting Co Ltd have been -5% over the past three years , 15% over the past five years , and 47% over the past ten years .

Back to Top